Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 50.50p 2,194 08:00:00
Bid Price Offer Price High Price Low Price Open Price
49.00p 52.00p 50.50p 50.50p 50.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.04 -20.97 -55.70 16.0

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron Forums and Chat

Date Time Title Posts
04/1/201913:23ReNeuron - a leading, clinical-stage stem cell business5,765
07/8/201708:10Interpretating Neil Woodfords. ..5
02/8/201711:05Interesting article...albeit lengthly5

Add a New Thread

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-01-22 16:08:5549.102,000982.00O
2019-01-22 11:23:4849.00500245.00O
2019-01-22 10:45:1549.101,028504.75O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 50.50p.
Reneuron Group has a 4 week average price of 47p and a 12 week average price of 47p.
The 1 year high share price is 145p while the 1 year low share price is currently 1.45p.
There are currently 31,646,186 shares in issue and the average daily traded volume is 35,780 shares. The market capitalisation of Reneuron Group is £15,981,323.93.
wigwammer: It looks like interest in regenerative medicine and it's potential in brain injury is about to take a step up. See attachment below. This is very good news for Reneuron IMO as they aim to partner the CTX line, and explains the slightly firmer share price in recent days. Market cap of SanBio is now £1.5bn, jumping 20% since the result. Market cap of Reneuron with comparable pipeline technology is £20m.
johnwise: 12 July 2018 RNS Number : 3788U ReNeuron Group plc Preliminary Results
wigwammer: Rocket fuel - a few years ago, I would have agreed with you. Two things have changed:1) the share price/valuation has fallen dramatically2) the drugs have progressed through the clinic...I'm up circa 40% here on my average entry price and suspect it's going a lot higher. You keep up the good work on that ph though and try and keep up :)
ashtree2: share price has been decimated by director selling otherwise can see no reason for this low price.only just recently seen this one and have taken a nibble.
billiondollarbrain: Immupharma (IMM) Phase III Lupuzor results expected this week. Possible $ multi-billion blockbuster could lead to a massive re-rating of the share price. This promising small-cap stock could be a millionaire maker in 2018 Paul Summers 26/12/2017 hTTps:// The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain. Blockbuster potential Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus. Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn. Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results. In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year. In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m. Tempted? If so, it’s vital to consider the flip side of this investment. Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio. That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt. That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period. No investment is devoid of risk but only you can decide whether this is one worth taking.
rotors: "Rotors 19 Dec '17 - 20:51 - 5386 of 5466 1. Boston office = NASDAQ quote?" ---------------------------------- If there is no NASDAQ quote (and US interest) forthcoming I fear we are in for a torrid time. Progress is slow, continued good news posts are met with a falling share price which is now below the cash value. I assume Mr Woodford was consulted on the share consolidation which seems to have backfired. There will also be sales up to the end of the tax year for those looking to offset gains elsewhere. A grim picture. (EDIT ..... for shareholders and those looking for medical progress)
gisjob2: Price will be 100x more but your share holding will be 100x less. Usually bad news for the share price at least in the short-term. Happened on a couple of shares I have owned and both drifted lower straight after. The value of 1p has nothing to do with the current or proposed share price.
rock star: Consolidation of shares usually means share price down over next few weeks.
dickbush: Thanks,algernon2 A very professional and positive presentation. However, he and the company seem to continue to have a major credibility problem-as judged by the share price. Despite record highs for the stockmarket, the share price is at an all-time low with holders, apparently, willing to sell no matter what the bid price.
alimo: Will never understand why prices go up and down on such small trading volume - I mean there are over 3bn shares in issue. I topped up a little today thinking there's RP news due in first half of this year, maybe MH will want to speak about it in Edinburgh next week. Someone is holding this back, though how they do it when Woodford , Toscafund, and Aviva are aboard and positive about it, beats me. Also Olaf H the CEO spent £10,000 adding 346,644 shares on 14th Dec 2016 to make his total 669,422, and even Michael H who's speaking on Wednesday, bought another 250,000 this week taking him to a total of 2,008,471. These two both have big share options exercisable subject to the achievement of the following performance conditions: 1) When the first patient is administered with a ReNeuron cell therapy in a sixth clinical trial, one third of the options will vest. 2) When the fourth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest. 3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest. The vesting criteria for the TSR-related performance condition above will also apply on a proportionate basis to TSR-related performance conditions attaching to prior share option grants under the LTIP. Well, perhaps someone here understands what the above means and what the share price will have to be at before they get the big bucks. Olaf H's options pot amounts to 33m+ shares, and Michael H's pot is 29m+. In the meantime they get big salaries while our shares languish in sweeties land. We already have come a long long way and are nearer, and getting nearer every day, to the good news outcomes the company was floated for at 25p back in Aug 2005 and reaching 46p in Jan 2007. Investors in those days must must have had a real long term vision for RENE. Hopefully our CEO and CFO have the same vision to turn our company share price back up to these dizzy levels, without selling us out to be gobbled up by the AZNs of this world, before adequate payback for the 20 years of loyalty.
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190123 09:14:46